Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
NCT05367973
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Vulvovaginal Atrophy
Vasomotor Symptoms
Interventions
DEVICE:
IVR Dose 1
DEVICE:
IVR Dose 2
Sponsor
Daré Bioscience, Inc.